Shilpa Medicare gets EIR from USFDA for Jadcherla facility

Updated: Sat, Oct 07, 2017
02:19 pm
PTI
RELATED NEWS
Expert Views: BIG! India's retail inflation eases to 4.59% in December Expert Views: BIG! India's retail inflation eases to 4.59% in December
Budget 2021 Expectations – HOME BUYERS to benefit if Govt accepts this demand; JLL CEO lists following demands Budget 2021 Expectations – HOME BUYERS to benefit if Govt accepts this demand; JLL CEO lists following demands
Jobs, land prices, Covid-19 vaccine, rural India, household savings, NBFCs, banks, consumption, capex - Positives and Negatives | EXPLAINED Jobs, land prices, Covid-19 vaccine, rural India, household savings, NBFCs, banks, consumption, capex - Positives and Negatives | EXPLAINED

Shilpa Medicare today said the USFDA has issued an Establishment Inspection Report (EIR) for its Jadcherla facility in Telangana.

The US health regulator has issued an EIR for the company's generic pharmaceutical manufacturing facility at Jadcherla, which was inspected between July 24-28, 2017, Shilpa Medicare said in a filing to BSE.

The inspection has now been closed by the USFDA, it added.

"The company had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines in response to the form 483 issued at the end of inspection," it said.

The USFDA has reviewed the CAPA and found it acceptable, it added.

 

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.